CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NUVL

Zidesamtinib (NVL-520)

Phase 2
Nuvalent, Inc. (NUVL)

Phase 2

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Past
days
NUVLPDUFA
Phase 2Positive

FDA PDUFA Date zidesamtinib

Zidesamtinib (NVL-520)
Sep 18
Source
Competitive Landscape

0 competitors in Locally Advanced Solid Tumor

View Full Landscape
Drug Information

Target Indication

Locally Advanced Solid Tumor

Clinical Trial

NCT05118789

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.